---
title: "Krystal Biotech Surges 5.02% on ~$389M VYJUVEK Revenue; DAWN Dips 3.35%"
canonical_url: https://www.stockexpertai.com/journal/2026-01-12/krystal-biotech-surges-502-on-389m-vyjuvek-revenue-dawn-dips-335
last_updated: 2026-01-12T06:08:47.160Z
section: "Earnings Watch"
author: "Taylor Brooks"
publisher: Stock Expert AI
tickers: KRYS, DAWN, KURA, SPY, DIA
content_type: journal-article
---

# Krystal Biotech Surges 5.02% on ~$389M VYJUVEK Revenue; DAWN Dips 3.35%

## The Take
- Biotech investors should focus on companies demonstrating strong revenue growth and clear paths to profitability in the competitive pharmaceutical landscape.

_Biotech earnings season kicks off with mixed results. Krystal shines, while Day One faces headwinds._

Earnings season brings clarity—and volatility. The biopharmaceutical sector is already providing a glimpse into what to expect, with several companies releasing preliminary results and 2026 guidance. Krystal Biotech (KRYS) is leading the pack, while Day One Biopharmaceuticals (DAWN) faces investor scrutiny.

Krystal Biotech (KRYS) reported preliminary unaudited 2025 VYJUVEK revenue of approximately $389 million, fueling a 5.02% surge in the stock. The company also boasts impressive cash reserves of $955 million. This strong performance underscores the potential of rare disease therapies and positions Krystal Biotech for continued growth. Investors are clearly optimistic about the company's strategic vision and its ability to capitalize on the unmet needs in the rare disease space.

Day One Biopharmaceuticals (DAWN), on the other hand, saw its stock dip 3.35% despite announcing a 172% year-over-year increase in preliminary 2025 OJEMDA net product revenue. The company also provided 2026 U.S. guidance, projecting revenue between $225 million and $250 million. While the revenue growth is significant, the market's reaction suggests that investors may be concerned about future profitability or competition in the pediatric cancer treatment market.

Meanwhile, Kura Oncology (KURA) announced $2.1 million in initial KOMZIFTI sales and secured a $195 million milestone. KURA closed down slightly at -1.47%. As earnings season progresses, attention will remain focused on companies' ability to not only meet but exceed expectations, and to provide clear and compelling guidance for the year ahead. The SPY is up 0.66% to $694.07 as earnings season begins.

## Related Tickers
- [KRYS](https://www.stockexpertai.com/stock/krys)
- [DAWN](https://www.stockexpertai.com/stock/dawn)
- [KURA](https://www.stockexpertai.com/stock/kura)
- [SPY](https://www.stockexpertai.com/stock/spy)
- [DIA](https://www.stockexpertai.com/stock/dia)

## Frequently Asked Questions

### What drove Krystal Biotech's stock surge?
Krystal Biotech's stock surged due to strong preliminary 2025 VYJUVEK revenue of approximately $389 million. This positive performance, coupled with a healthy cash reserve, fueled investor optimism about the company's growth potential in the rare disease therapy market.

### Why did Day One Biopharmaceuticals' stock decline despite revenue growth?
Day One Biopharmaceuticals' stock dipped despite significant revenue growth because investors may be concerned about future profitability or competition in the pediatric cancer treatment market. The market's reaction suggests that the announced revenue, while positive, didn't fully meet expectations or address concerns about the company's long-term prospects.

---
_AI-generated under human editorial supervision. Educational research, not financial advice._